Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes

Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats

(2011) Seung Jin Han et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice

(2011) Y. Takeda et al.   DIABETOLOGIA

FTY720 Normalizes Hyperglycemia by Stimulating β-Cellin VivoRegeneration indb/dbMice through Regulation of Cyclin D3 and p57KIP2

(2011) Zhengshan Zhao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus

(2010) J. J. Neumiller et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Sitagliptin prevents the development of metabolic and hormonal disturbances, increased β-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats

(2010) Bárbara Maiztegui et al.   CLINICAL SCIENCE

The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats

(2010) F. R. Macdonald et al.   DIABETES OBESITY & METABOLISM

Effects of chronic administration of alogliptin on the development of diabetes and β-cell function in high fat diet/streptozotocin diabetic mice

(2010) X. Zhang et al.   DIABETES OBESITY & METABOLISM

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis

(2010) Jae Min Cho et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Preservation of Beta-Cell Function in Type 2 Diabetes

(2010) Kavita Nyalakonda et al.   Endocrine Practice

Combination Therapy with Nateglinide and Vildagliptin Improves Postprandial Metabolic Derangements in Zucker Fatty Rats

(2010) K. Miura et al.   HORMONE AND METABOLIC RESEARCH

A Physiologic and Pharmacological Basis for Implementation of Incretin Hormones in the Treatment of Type 2 Diabetes Mellitus

(2010) Jeffrey S. Freeman   MAYO CLINIC PROCEEDINGS

Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus

(2010) Joshua J Neumiller et al.   PHARMACOTHERAPY

Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition

(2009) Mark Kirby et al.   CLINICAL SCIENCE

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

(2009) J. Rosenstock et al.   CURRENT MEDICAL RESEARCH AND OPINION

Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin

(2009) A. V. Matveyenko et al.   DIABETES

Glucagon-Like Peptide-1 Protects  -Cells Against Apoptosis by Increasing the Activity of an Igf-2/Igf-1 Receptor Autocrine Loop

(2009) M. Cornu et al.   DIABETES

Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and β-cell damage in diabetic mice

(2009) Y. Furuta et al.   DIABETES OBESITY & METABOLISM

Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes

(2009) James Mu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Exploration of the DPP-4 inhibitors with a focus on saxagliptin

(2009) Jay H Shubrook et al.   EXPERT OPINION ON PHARMACOTHERAPY

Fate of the beta-cell in the pathophysiology of type 2 diabetes

(2009) R. Keith Campbell   JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION

Prevalence, Treatment, and Control of Diagnosed Diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004

(2008) Kwok Leung Ong et al.   ANNALS OF EPIDEMIOLOGY

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study

(2008) R. A. DeFronzo et al.   DIABETES CARE

Efficacy and tolerability of vildagliptin in drug-nave patients with type 2 diabetes and mild hyperglycaemia

(2008) W. A. Scherbaum et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

(2008) Viswanathan Mohan et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Acute Dipeptidyl Peptidase-4 Inhibition Rapidly Enhances Insulin-Mediated Suppression of Endogenous Glucose Production in Mice

(2008) Hélène Duez et al.   ENDOCRINOLOGY

Chronic Treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356 [(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models

(2008) L. Thomas et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS